• Background
logo
  • Home
  • Who we are
    Who we are
    • Overview
    • Chairman's Profile
    • Board of Directors
    • Team Wockhardt
    • Collaborations / Partnerships
    Faclities
    • Manufacturing
    • Contract Manufacturing
    • Virtual Tour
    Global Presence
    • Our Footprints
    • Other websites
    Community Care
    • Wockhardt Foundation
  • We touch lives
    R & D
    • Overview
    • Generics
    • New Drug Discovery
    Biotechnology
    • Overview
    • Biopharmaceuticals
    • Biotechnology Park
    • Gallery
    Corporate Regulatory
    • Marketing & Regulatory Infrastructure
  • Products
    • Search Products
  • People
    • Frequently Asked Questions
    • Life at Wockhardt
    • Focus on Development
    • Wockhardt Anthem
    • Meet our People
    • Wockhardt on LinkedIn
    • Career Openings
  • Investors
    • Financials at a glance
    • Annual Reports
    • AGM Notice
    • Chairman's AGM Speeches
    • Other Shareholders Services
    • Quarterly Results
    • Financial Press Releases
    • Chairman's letter to Shareowners
    • Details of Unclaimed Dividend
    • Filings with Stock Exchange
    • Shareholding Pattern
    • Stock Quotes
    • Statutory Communication
    • Policies
    • Credit Rating
    • Investor Communication
    • Investor Meet
    • Investor Contact
    • Investor Call
    • Accounts of Subsidiaries
  • Media & Press
    • Media coverage
    • Press Release
    • Media Kit
    • Media Contact
  • CSR
    • CSR Policy
    • Report on CSR activities – Wockhardt Foundation
    • CSR Strategy
    • Quarterly Report
    • Stakeholders Engagement
  • Home
  • >
  • Media
  • >
  • Press Releases

Press Releases

Press releases

Wockhardt Press Releases

Archives
123Prev
Wockhardt and Serum Life Sciences UK announce collaboration for manufacturing multiple vaccines in the United Kingdom
20 March, 2022
National Institutes of Health (NIH), USA to conduct human Phase 1 trial of Wockhardt’s novel once-a-day MDR Gram-negative antibiotic WCK 6777
16 March, 2022
Wockhardt gets CDSCO nod for exporting up to 100 million doses of Sputnik Vaccines
08 February, 2022
Q3 (Oct-Dec 2021) Financial Results FY22
27 January, 2022
Q2 (Jul-Sept 2021) Financial Results FY22
08 November, 2021
Wockhardt and Jemincare partner for novel respiratory antibiotic Nafithromycin
26 August, 2021
RDIF and Wockhardt partner to produce Sputnik V and Sputnik Light vaccines against COVID-19
13 August, 2021
Hugely successful vaccination roll out made possible by UK - Indian business partnership
27 July, 2021
Q1 (Apr-Jun 2021) Financial Results FY22
22 July, 2021
Wockhardt UK proudly hosts visit of HRH The Prince of Wales
05 July, 2021
123Prev
Get in touch
  • Corporate Office
  • International Offices
  • Research Centres
  • Manufacturing Plants
  • Adverse Event Reporting
  • SITEMAP
  • TERMS & CONDITIONS
  • Privacy Policy
wock-stock
For Registered Office / CIN etc. details,
please click here.
© 2016 wockhardt. All Rights Reserved.